Table 3 Association of LINE-1 methylation levels with risk of MS and clinical activity.

From: Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment

 

OR

IC 95%

p value

Model 1 (risk of MS):

Age

1.063

1.004–1.125

0.035

Gender (female vs. male)

2.242

0.781–6.438

n.s.

Model 2 (risk of MS):

LINE-1 methylation levels (high vs. low)

6.992

1.927–24.763

0.003

Age

1.073

1.011–1.139

0.021

Gender (female vs. male)

4.456

1.222–16.240

0.024

Model 3 (clinical activity):

LINE-1 methylation levels (high vs. low)

11.046

1.605–76.046

0.015

Age

0.939

0.865–1.020

n.s.

Gender (female vs. male)

1.764

0.239–13.02

n.s.

  1. Dependent variable in model 1 and 2: risk of MS (0: control; 1: non-treated MS patients). Dependent variable in model 3: clinical activity status after one year of treatment (0: without clinical activity; 1: with clinical activity). Low LINE-1 methylation: below the 75th percentile in the control group. High LINE-1 methylation: above the 75th percentile in the control group.
Back to article page